Phospholipid mediators in the vessel wall: involvement in atherosclerosis
Author:
- 1 March 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 8 (2) , 123-131
Abstract
This review provides a brief update on the involvement of major phospholipid mediators, with the emphasis on platelet-activating factor and its analogues generated upon the oxidation of lipoproteins in vascular pathology, including atherogenesis. Phospholipid mediators are produced during inflammation by various enzymes, mostly from pre-existing membrane phospholipids, and trigger cellular signaling via G-coupled receptors. A short description of lysophosphatidic acid, lysophosphocholine and sphingosine-1 phosphate receptors and their actions is given, but attention is focused mainly on platelet-activating factor and its analogues. The majority of these mediators participate in leukocyte adhesiveness to the endothelium, leukocyte transmigration into the vessel wall and the subsequent formation of various chemokines leading to foam cell formation and smooth muscle cell proliferation and dedifferentiation. Platelet-activating factor and platelet-activating factor-like phospholipids are degraded in plasma by the lipoprotein-bound enzyme of myeloid origin, PAF-acetylhydrolase, also known as LDL-PLA2. Although the overexpression of PAF-acetylhydrolase shows marked anti-atherogenic properties in animal models, epidemiological data in the Caucasian population have demonstrated that its level might be a risk factor for cardiovascular disease. Recent genetic studies have shown, however, that the A379V polymorphism of this gene, responsible for slightly higher enzymatic activity, exerts a protective effect, probably by modifying the enzyme function towards a less atherogenic form. Phospholipid-borne mediators are certainly key players in inflammation and thus in atherosclerosis. The generation of such biologically active molecules is possibly dependent on nutritional habits and the availability of antioxidants, including enzymes protective against oxidative damage, including PAF-acetylhydrolase.Keywords
This publication has 87 references indexed in Scilit:
- The ins and outs of lysophosphatidic acid signalingBioEssays, 2004
- Phosphorylation of STAT-3 in Response to Basic Fibroblast Growth Factor Occurs through a Mechanism Involving Platelet-activating Factor, JAK-2, and Src in Human Umbilical Vein Endothelial CellsJournal of Biological Chemistry, 2002
- Cellular Source(s) of Platelet-Activating-Factor Acetylhydrolase Activity in PlasmaBiochemical and Biophysical Research Communications, 1999
- Copper-Catalyzed Oxidation Mediates PAF Formation in Human LDL SubspeciesArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.Journal of Clinical Investigation, 1995
- PAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human PlasmaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Platelet-activating factor and its analogs: metabolic pathways and related intracellular processesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Platelet-aggregating effects of platelet-activating factor-like phosphollpids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl groupBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Biosynthesis of paf-acether XIV. Paf-acether output in murine peritoneal macrophages is regulated by the level of acetylhydrolaseBiochemical and Biophysical Research Communications, 1989
- Effect of Dietary Enrichment with Eicosapentaenoic and Docosahexaenoic Acids on in Vitro Neutrophil and Monocyte Leukotriene Generation and Neutrophil FunctionNew England Journal of Medicine, 1985